Literature DB >> 10455367

Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry.

R Martino1, P Romero, M Subirá, M Bellido, A Altés, A Sureda, S Brunet, I Badell, J Cubells, J Sierra.   

Abstract

Acute graft-versus-host disease (AGVHD) severity is usually graded (grades 0-IV) by the pattern of organ involvement using the classic Glucksberg-Seattle criteria (GSC). Recently, the International Bone Marrow Transplant Registry (IBMTR) developed a new Severity Index by regrouping the patterns of organ involvement into five Indexes (0-D) that appeared more predictive of transplant-related mortality (TRM) and transplant failure (TF, relapse or TRM). We studied the predictive value of both grading systems of TRM, TF and GVHD-related mortality (GTRM) in a series of 114 consecutive patients > or = 12 years old allografted from a histocompatible sibling at our institution, 100 of whom were evaluable for AGVHD. The IBMTR Severity Index showed better incremental prediction of TRM (relative risks (RR) of 1, 1.5, 1.4, 2 and 2.5 for Indexes 0, A, B, C and D), TF (RRs of 1, 1.6, 1.6, 2 and 2.3, respectively) and GTRM (RRs of 1, 2.2 and 4.8 for Indexes B, C and D) than the GSC. With the GSC different outcomes for TRM and TF were found only from grade 0 to I-II and 0 to IV or I-III to IV, but not from I-II to III. The GSC also appeared less predictive of GTRM (RRs of 1, 0.4 and 2.9 for grades II, III and IV). In our relatively small patient sample, the new IBMTR Severity Index appeared more predictive of transplant outcome than the GSC, especially between no AGVHD, early Indexes (A-B) and advanced Indexes (C-D).

Entities:  

Mesh:

Year:  1999        PMID: 10455367     DOI: 10.1038/sj.bmt.1701899

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  18 in total

1.  Sole Upfront Therapy with Beclomethasone and Budesonide for Upper Gastrointestinal Acute Graft-versus-Host Disease.

Authors:  Chiara Frairia; Maura Nicolosi; Jamie Shapiro; Jongphil Kim; Brian C Betts; Hugo F Fernandez; Frederick L Locke; Asmita Mishra; Taiga Nishihori; Jose Leonel Ochoa-Bayona; Lia Perez; Joseph Pidala; Claudio Anasetti
Journal:  Biol Blood Marrow Transplant       Date:  2020-04-30       Impact factor: 5.742

2.  A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.

Authors:  Margaret L MacMillan; Marie Robin; Andrew C Harris; Todd E DeFor; Paul J Martin; Amin Alousi; Vincent T Ho; Javier Bolaños-Meade; James L M Ferrara; Richard Jones; Mukta Arora; Bruce R Blazar; Shernan G Holtan; David Jacobsohn; Marcelo Pasquini; Gerard Socie; Joseph H Antin; John E Levine; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-10       Impact factor: 5.742

3.  Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years.

Authors:  Vipul Sharad Sheth; Victoria Potter; Shreyans A Gandhi; Austin Gladston Kulasekararaj; Hugues de Lavallade; Petra Muus; Antonio Pagliuca; Carmel F M Rice; Varun Mehra; Francesco Grimaldi; Shafqat Inam; Linda D Barber; Ghulam J Mufti; Judith C Marsh
Journal:  Blood Adv       Date:  2019-10-22

4.  Regional intra-arterial steroid treatment in 120 patients with steroid-resistant or -dependent GvHD.

Authors:  M Y Shapira; A Klimov; S Vipul; S Grisariu; B R Avni; R Or; A I Bloom
Journal:  Bone Marrow Transplant       Date:  2017-06-26       Impact factor: 5.483

5.  What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score.

Authors:  Margaret L MacMillan; Todd E DeFor; Daniel J Weisdorf
Journal:  Br J Haematol       Date:  2012-04-06       Impact factor: 6.998

6.  Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study.

Authors:  Jean-Yves Cahn; John P Klein; Stephanie J Lee; Noël Milpied; Didier Blaise; Joseph H Antin; Véronique Leblond; Norbert Ifrah; Jean-Pierre Jouet; Fausto Loberiza; Olle Ringden; A John Barrett; Mary M Horowitz; Gérard Socié
Journal:  Blood       Date:  2005-05-05       Impact factor: 22.113

7.  Clinical outcomes of individualized busulfan-dosing in hematopoietic stem cell transplantation in Chinese children undergoing with therapeutic drug monitoring.

Authors:  Duan-Fang Shao; Jun-Hui Li; Tao Hu; Zhao-Xia Zhang; Lei Zhang; Juan-Juan Li; Jing Cao; Shun-Qiao Feng; Rui-Hong Tang; Di-Xiao Zhong; Ze-Liang Song; Mei Yue; Meng-Ze Hu; Li-Tian Xuan; Meng-Na Zhai; Hai-Feng Zhang; Xiang-Yan Wang; Xiao-Dong Shi; Rong Liu
Journal:  Bone Marrow Transplant       Date:  2022-01-17       Impact factor: 5.174

8.  Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.

Authors:  Xavier Poiré; Andrew Artz; Richard A Larson; Justin Kline; Olatoyosi Odenike; Elizabeth Rich; Lucy Godley; Wendy Stock; Koen van Besien
Journal:  Leuk Lymphoma       Date:  2009-01

9.  MicroRNA-181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN-γ production.

Authors:  Wei Sang; Cong Zhang; Dianzheng Zhang; Ying Wang; Cai Sun; Mingshan Niu; Xiaoshen Sun; Cui Zhou; Lingyu Zeng; Bin Pan; Wei Chen; Dongmei Yan; Feng Zhu; Qingyun Wu; Jiang Cao; Kai Zhao; Chong Chen; Zhenyu Li; Depeng Li; Thomas P Loughran; Kailin Xu
Journal:  Am J Hematol       Date:  2015-10-08       Impact factor: 10.047

10.  Mixed T cell lineage chimerism in acute leukemia/MDS using pre-emptive donor lymphocyte infusion strategy-Is it prognostic?-a single-center retrospective study.

Authors:  Donal Mclornan; Kavita Raj; Vipul Sheth; Victoria Potter; Hugues de Lavallade; Shreyans Gandhi; Austin Kulasekararaj; Pramila Krishnamurthy; Varun Mehra; Francesco Dazzi; Ghulam Mufti; Antonio Pagliuca
Journal:  Blood Cancer J       Date:  2021-07-12       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.